| Afatinib - Wikipedia, the free encyclopedia Afatinib (INN ; planned trade name Tomtovok, previously Tovok) is a candidate drug against non-small cell lung carcinoma, developed by Boehringer Ingelheim. As of ... Read More |
| Angiokinase inhibitors - Wikipedia, the free encyclopedia BIBW 2992 is a promising treatment for patients with NSCLC who have either primary (exon 20 insertion) or acquired (T790M) erlotinib resistance mutations. BIBW 2992 ... Read More |
| Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A ... Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel ... Read More |
| Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung ... Secondary Outcome Measures: Safety of BIBW 2992 when administered together with cetuximab as indicated by intensity and incidence of adverse events, graded ... Read More |
| Use of BIBW 2992, a novel irreversible EGFR/HER2 TKI, to induce ... Home > Meetings > Abstracts ... The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique ... Read More |
| A phase I dose escalation study of BIBW 2992, an irreversible dual ... We are sorry, but NCBI web applications do not support your browser, and may not function properly. More information here... Read More |
| BIBW-2992, a dual receptor tyrosine kinase inhibitor for the ... 1. Curr Opin Investig Drugs. 2008 Dec;9(12):1336-46. BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Minkovsky N, Berezov A. Read More |
| BIBW2992 (Afatinib) | EGFR Inhibitor | Buy BIBW2992 (Afatinib ... BIBW2992 (Afatinib, Tomtovok, Tovok) inhibits EGFR/HER2 irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14 nM for EGFR wt , EGFR L858R , EGFR ... Read More |
| BIBW 2992 cancer treatment data presented at ASCO Further data on BIBW 2992 suggests it is at least as effective as cetuximab in head & neck cancer, and reaffirms activity in NSCLC with EGFR mutations. Read More |
| Press Release Archive: Oncology - Boehringer Ingelheim ... 21 May 2010 Boehringer Ingelheim’s lead investigational oncology compound BIBW 2992 demonstrates potential as a next generation treatment for non-small cell lung ... Read More |
